Symbol="CRNX"
AssetType="Common Stock"
Name="Crinetics Pharmaceuticals Inc"
Description="Crinetics Pharmaceuticals, Inc., a clinical-stage pharmaceutical company, focuses on the discovery, development, and commercialization of therapies for rare endocrine diseases and endocrine-related tumors. The company is headquartered in San Diego, California."
CIK="1658247"
Exchange="NASDAQ"
Currency="USD"
Country="USA"
Sector="LIFE SCIENCES"
Industry="PHARMACEUTICAL PREPARATIONS"
Address="10222 BARNES CANYON ROAD, BLDG. #2, SAN DIEGO, CA, US"
FiscalYearEnd="December"
LatestQuarter="2023-06-30"
MarketCapitalization="934047000"
EBITDA="-190892000"
PERatio="None"
PEGRatio="None"
BookValue="4.647"
DividendPerShare="0"
DividendYield="0"
EPS="-3.52"
RevenuePerShareTTM="0.09"
ProfitMargin="0"
OperatingMarginTTM="-39.72"
ReturnOnAssetsTTM="-0.336"
ReturnOnEquityTTM="-0.574"
RevenueTTM="4834000"
GrossProfitTTM="-125488000"
DilutedEPSTTM="-3.52"
QuarterlyEarningsGrowthYOY="0"
QuarterlyRevenueGrowthYOY="1.251"
AnalystTargetPrice="45.22"
TrailingPE="-"
ForwardPE="-"
PriceToSalesRatioTTM="171.68"
PriceToBookRatio="2.49"
EVToRevenue="99.87"
EVToEBITDA="-3.393"
Beta="0.865"
num_52WeekHigh="24.58"
num_52WeekLow="15.23"
num_50DayMovingAverage="18.45"
num_200DayMovingAverage="18.71"
SharesOutstanding="54687000"
DividendDate="None"
ExDividendDate="None"
symbol="CRNX"
open="17.38"
high="17.38"
low="16.76"
price="17.08"
volume="410378.00"
latest_trading_day="2023-08-25"
previous_close="17.19"
change="-0.11"
change_percent="-0.6399%"
aroon_positive_momentum_days="0"
aroon_negative_momentum_days="46"
trend_strength="Absent or Weak Trend"
buying_signal="Strong Sell Signal"
volume_analysis="Target Volume"
value_analysis="Expected Range"
Aroon_change="FALSE"
Aroon_momentum="54"
Volume_recent_avg="470485"
Change_recent_avg="-0.02"
Delta_recent_avg="0.84"
Variance_recent_avg="0.42"
Change_ratio_recent_avg="-0.14"
RSI_change="FALSE"
ADX_change="FALSE"

event="FALSE"
Aroon_signal="negative"
Aroon_change="FALSE"
Aroon_momentum_positive="54"
Aroon_momentum_negative="46"
image_negative_thumbnail_id_1="127"
image_negative_url_1="https://hehge.com/wp-content/uploads/sites/16/2023/05/MI_Finance_Negative_Landscape_0049.jpeg"
image_negative_thumbnail_id_2="1139"
image_negative_url_2="https://hehge.com/wp-content/uploads/sites/16/2023/06/MI_Finance_Negative_Landscape_0172.jpeg"
image_neutral_thumbnail_id_1="594"
image_neutral_url_1="https://hehge.com/wp-content/uploads/sites/16/2023/06/MI_Finance_Neutral_Landscape_0005.jpeg"
image_neutral_thumbnail_id_2="574"
image_neutral_url_2="https://hehge.com/wp-content/uploads/sites/16/2023/06/MI_Finance_Neutral_Landscape_0025.jpeg"
image_positive_thumbnail_id_1="631"
image_positive_url_1="https://hehge.com/wp-content/uploads/sites/16/2023/06/MI_Finance_Positive_Landscape_0077.jpeg"
image_positive_thumbnail_id_2="658"
image_positive_url_2="https://hehge.com/wp-content/uploads/sites/16/2023/06/MI_Finance_Positive_Landscape_0050.jpeg"
image_professor_thumbnail_id_1="1182"
image_professor_url_1="https://hehge.com/wp-content/uploads/sites/16/2023/06/MI_Finance_Professor_Landscape_0016.jpeg"
image_professor_thumbnail_id_2="1178"
image_professor_url_2="https://hehge.com/wp-content/uploads/sites/16/2023/06/MI_Finance_Professor_Landscape_0012.jpeg"
